Announced
Completed
Synopsis
Lightspeed Venture Partners, a venture capital firm, Vida Ventures, a next-generation life sciences investment firm, and MPM Capital, a biotechnology investment firm, led a $51m Series A round in Protego Biopharma, a preclinical-stage biotechnology company. “Protego is building on compelling science to develop small molecule therapeutics targeting protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases, and an area with enormous unmet medical need. We are thrilled to partner with a world-class investor syndicate during this pivotal stage as we accelerate the science from research to potentially delivering impactful medicines for patients,” Richard Labaudinière, Protego President and Chief Executive Officer.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.